Reviews of infectious diseases 1982-01-01

Combination of trimethoprim with sulfonamides other than sulfamethoxazole.

L S Bernstein

Index: Rev. Infect. Dis. 4(2) , 411-8, (1982)

Full Text: HTML

Abstract

Early in the development of trimethoprim (TMP), the response to the drug was less than enthusiastic. Preliminary clinical trials were performed with sulfonamides that were unsuitable partners. On the basis of bacteriologic and pharmacokinetic evidence, sulfamethoxazole (SMZ) was chosen for the fixed-ratio (5:1) combination with TMP. Possible criteria on which to base the choice of a sulfonamide partner for TMP have been delineated. The theoretical considerations may be questioned in view of limited clinical experience with some combinations and lack of controlled comparisons in well-designed clinical trials with others. Objective proof of the clinical superiority of newer TMP-sulfonamide combinations over TMP-SMZ is required.


Related Compounds

Related Articles:

Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis.

1996-03-01

[Adverse Drug React. Toxicol. Rev. 15(1) , 9-50, (1996)]

Use of p-benzoquinone for the spectrophotometric determination of certain sulphonamides.

1991-01-01

[J. Pharm. Biomed. Anal. 9(7) , 531-8, (1991)]

Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.

1982-09-01

[Br. J. Clin. Pharmacol. 14(3) , 437-43, (1982)]

[Supristol suspension in pediatrics].

1980-12-01

[Lille Med. 25(10) , 611-2, (1980)]

Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.

2015-09-01

[J. Endocrinol. 91(2) , 299-303, (1981)]

More Articles...